MetaCap

AC Immune SA (ACIU) vs Yarrow Bioscience (YARW)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Yarrow Bioscience (YARW) has outperformed AC Immune SA (ACIU) over the past year, losing 26.7% versus a loss of 35.0%. Over five years, ACIU leads with a -62.3% price change compared with -98.6% for YARW. Yarrow Bioscience is the larger company by market cap ($196.5 million vs $193.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACIU-35.00%YARW-26.70%
+172%+64%-45%
Nov 21, 20251 yearNov 20, 2026
ACIU-64.35%YARW-98.66%
+47%-29%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACIU versus YARW key metrics
MetricACIUYARW
Share price$1.95$12.90
Market cap$193.88M$196.53M
1-day change-8.45%-9.35%
YTD return-37.90%-55.52%
1-year return-35.00%-26.70%
5-year return-62.28%-98.61%
Forward P/E2.84—
EPS (TTM)$-0.44—
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$570.00K
Revenue growth (YoY)—+13.77%
Net income (latest FY)—$-26.48M
Operating margin—-5219.12%
Net margin—-4646.14%
52-week high$3.90$46.95
52-week low$1.93$12.39
Distance from 52-week high-50.00%-72.52%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+331.28%+310.85%
Average volume198.81K153.34K
Shares outstanding99.43M15.23M
Employees907
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About AC Immune SA

ACIU stock →

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 90 employees

About Yarrow Bioscience

YARW stock →

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees

ACIU vs YARW FAQ

Which is bigger, AC Immune SA or Yarrow Bioscience?

Yarrow Bioscience (YARW) is larger, with a market capitalization of $196.53M compared with $193.88M for AC Immune SA (ACIU).

Which stock has performed better over the past year, ACIU or YARW?

YARW returned -26.70% over the past 12 months, compared with -35.00% for ACIU (price return, excluding dividends). Past performance does not predict future results.

Are AC Immune SA and Yarrow Bioscience in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons